The file's text, extracted by GovTribe without its formatting.
NOI
The Defense Health Agency (DHA) intends to award a sole source bridge contract under the authority of 41 U.S.C. 1901, to QUIDELORTHO SALES COMPANY, LLC 9975 Summers Ridge Road San Diego, California 92121-2997, United States, 84107 for the provision of all services, materials, and equipment necessary to provide required analyzer, assays, reagents and consumables to the 633rd Medical Group at Langley-Eustis Air Force Base in Hampton, VA. The period of performance of the bridge contract is 2 December 2025 through 30 September 2026 with 1 (one) 6-month option period.
Quidelortho will provide two (2) Integrated System Cost Per Reportable Chemistry Analyzers with the most current/modern technology available within the commercial industry, test equipment and associated power ware, and all validation supplies and reagents. The contractor shall provide all support needed to include equipment repairs, labor, travel and materials not government furnished, necessary to keep both units operational to manufacturer’s specifications 24 hours per day, seven (7) days per week. The contractor shall provide troubleshooting assistance, as requested, 24 hours per day, 7 days per week.
Estimated Period of Performance: 2 December 2025 through 30 September 2026
| Test Nomenclature |
| Estimated Count |
| Alkaline Phosphatase |
| 25000 |
| Aspartate Amino Transferase |
| 25000 |
| Blood Urea Nitrogen |
| 25833 |
| Direct/Indirect Bilirubin |
| 15070 |
| Gamma Glutamyl Transferase |
| 2802 |
| High Density Lipoprotein |
| 18667 |
| Lactate Dehydrogenase |
| 3264 |
BNP
| Low Density Liproprotein, Direct |
| 9500 |
There are no set-aside restrictions for this requirement. The intended procurement will be classified under North America Industry Classification System (NAICS) 334516. This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit sufficient technical data to determine capability in providing the same product. All capability statements received by the closing date of this synopsis will be considered by the Government. Information received will be considered solely for the purpose of determining whether to conduct competitive procurement. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government.
Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information, or submissions that only ask questions will not be considered as an affirmative response. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government.
Capability statements are due by 2:00 PM EST, 10 November 2025. Capability statements shall be submitted by e- mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: karl.o.molina.civ@health.mil.
IN SUBJECT LINE REFERENCE: "1 2025 HT9406 NOI Bridge Analyzer".
Defense Health Agency